Moreover, both troglitazone (TZD) treatment and obesity decreased GPX1 and GPX3 protein levels in adipose tissue, being indicative of low contribution of adipose tissue GPX to serum GPX activity [172]. The gene discussed is GPX1; the disease is obesity disorder.